Ethambutol
Antimycobacterial — ANTIINFECTIVES FOR SYSTEMIC USE
Also known as: (S,S)-Ethambutol, diambutol, etambutol, ethambutol dihydrochloride, ethambutol HCl, ethambutol hydrochloride
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Ethambutol is an ofp drug in the Antimycobacterial class catalogued in DrugCentral. It was first approved by the FDA in 1967. DrugCentral lists 9 molecular targets, including CYP3A4, HTR2A and HTR2C. Recorded indications include Acute tuberculosis and Pulmonary tuberculosis.
- Approval status: ofp (first approved 1967 by the FDA).
- Drug class: Antimycobacterial.
- Molecular targets: CYP3A4, HTR2A, HTR2C and HTR2B (9 listed in DrugCentral).
- Indications: Acute tuberculosis and Pulmonary tuberculosis.
- ATC code: J04AK02 (Other drugs for treatment of tuberculosis).
- Molecular formula: C10H24N2O2; molecular weight 204.31 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Acute tuberculosis
- Pulmonary tuberculosis
Off-label uses (3)
- Atypical mycobacterial infection
- Pulmonary Mycobacterium avium complex infection
- Tuberculosis of meninges
Contraindications (5)
- Bilateral cataracts
- Diabetic retinopathy
- Gout
- Kidney disease
- Optic neuritis
Mechanism & targets
| Established pharmacologic class | Antimycobacterial |
|---|
Molecular targets (9)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Cytochrome P450 3A4 | CYP3A4 | unknown | IC50 6.25 |
| 5-hydroxytryptamine receptor 2A | HTR2A | unknown | IC50 5.48 |
| 5-hydroxytryptamine receptor 2C | HTR2C | unknown | IC50 5.16 |
| 5-hydroxytryptamine receptor 2B | HTR2B | unknown | IC50 5.15 |
| Cytochrome P450 3A5 | CYP3A5 | unknown | IC50 4.72 |
| Probable arabinosyltransferase A | embA | inhibitor | — |
| Probable arabinosyltransferase A | embA | unknown | — |
| Probable arabinosyltransferase B | embB | unknown | — |
| Probable arabinosyltransferase C | embC | unknown | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1967-11-06 | FDA | — | STI PHARMA LLC |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
J04AK02 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOBACTERIALS › DRUGS FOR TREATMENT OF TUBERCULOSIS › Other drugs for treatment of tuberculosis |
J04AM03 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOBACTERIALS › DRUGS FOR TREATMENT OF TUBERCULOSIS › Combinations of drugs for treatment of tuberculosis |
J04AM06 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOBACTERIALS › DRUGS FOR TREATMENT OF TUBERCULOSIS › Combinations of drugs for treatment of tuberculosis |
J04AM07 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOBACTERIALS › DRUGS FOR TREATMENT OF TUBERCULOSIS › Combinations of drugs for treatment of tuberculosis |
J04AM09 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOBACTERIALS › DRUGS FOR TREATMENT OF TUBERCULOSIS › Combinations of drugs for treatment of tuberculosis |
J04AM10 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOBACTERIALS › DRUGS FOR TREATMENT OF TUBERCULOSIS › Combinations of drugs for treatment of tuberculosis |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Paradoxical drug reaction | 1984.8 |
| Drug reaction with eosinophilia and systemic symptoms | 1456.0 |
| Immune reconstitution inflammatory syndrome | 1429.0 |
| Drug resistance | 1335.4 |
| Drug-induced liver injury | 1114.3 |
| Immune reconstitution inflammatory syndrome associated tuberculosis | 769.0 |
| Drug interaction | 647.9 |
| Mycobacterium avium complex infection | 558.9 |
| Hepatotoxicity | 554.5 |
| Optic neuropathy | 513.1 |
| Acute hepatic failure | 356.3 |
| Tuberculosis | 354.2 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Ethambutol is on its molecule page.
| Molecular formula | C10H24N2O2 |
|---|---|
| Molecular weight | 204.31 g/mol |
| CAS number | 74-55-5 |
| InChIKey | AEUTYOVWOVBAKS-UWVGGRQHSA-N |
| PubChem CID | 14052 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Ethambutol used for?
DrugCentral lists the following indications for Ethambutol: Acute tuberculosis and Pulmonary tuberculosis.
How does Ethambutol work?
Its molecular targets in DrugCentral include CYP3A4, HTR2A, HTR2C and HTR2B.
When was Ethambutol first approved?
Ethambutol was first approved by the FDA in 1967.
What drug class does Ethambutol belong to?
Ethambutol is in the Antimycobacterial class.
What is the chemical formula of Ethambutol?
Ethambutol has the molecular formula C10H24N2O2 and a molecular weight of 204.31 g/mol.
Browse: all drugs starting with E · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1073 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3140361 — compound record and bioactivity
- PubChem CID 14052 — chemical identifiers
- DrugBank DB00330 — drug record
- FDA UNII 8G167061QZ — substance identity
- DailyMed: FDA labels for Ethambutol — current prescribing information (label search)
- UniProt P08684 (CYP3A4) — target protein
- UniProt P28223 (HTR2A) — target protein
- UniProt P28335 (HTR2C) — target protein
- UniProt P41595 (HTR2B) — target protein
- UniProt P20815 (CYP3A5) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.